Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

Constantine S. Tam, Hagop Kantarjian, Guillermo Garcia-Manero, Gautam Borthakur, Susan O'Brien, Farhad Ravandi, Jenny Shan, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, patients achieving a major cytogenetic response (12MMCyR) had a significant survival advantage over patients in minor cytogenetic response or complete hematologic response, with a projected one-year survival of 97% and 84% respectively (P = .02). Projected 1-year progression to hematologic failure, accelerated phase, or blast phase was also significantly different (3% vs 17%, P =.003). Early cytogenetic response was strongly predictive of achievement of 12MMCyR, with less than 10% of patients showing no cytogenetic response at 3 to 6 months eventually attaining the target of 12MMCyR. These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies.

Original languageEnglish (US)
Pages (from-to)516-518
Number of pages3
JournalBlood
Volume112
Issue number3
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Protein-Tyrosine Kinases
Therapeutics
Blast Crisis
Survival
Complementary Therapies
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib
Imatinib Mesylate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. / Tam, Constantine S.; Kantarjian, Hagop; Garcia-Manero, Guillermo; Borthakur, Gautam; O'Brien, Susan; Ravandi, Farhad; Shan, Jenny; Cortes, Jorge.

In: Blood, Vol. 112, No. 3, 01.08.2008, p. 516-518.

Research output: Contribution to journalArticle

Tam, Constantine S. ; Kantarjian, Hagop ; Garcia-Manero, Guillermo ; Borthakur, Gautam ; O'Brien, Susan ; Ravandi, Farhad ; Shan, Jenny ; Cortes, Jorge. / Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. In: Blood. 2008 ; Vol. 112, No. 3. pp. 516-518.
@article{41c8a638d073462eb88bad0c0f9bd14d,
title = "Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia",
abstract = "To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, patients achieving a major cytogenetic response (12MMCyR) had a significant survival advantage over patients in minor cytogenetic response or complete hematologic response, with a projected one-year survival of 97{\%} and 84{\%} respectively (P = .02). Projected 1-year progression to hematologic failure, accelerated phase, or blast phase was also significantly different (3{\%} vs 17{\%}, P =.003). Early cytogenetic response was strongly predictive of achievement of 12MMCyR, with less than 10{\%} of patients showing no cytogenetic response at 3 to 6 months eventually attaining the target of 12MMCyR. These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies.",
author = "Tam, {Constantine S.} and Hagop Kantarjian and Guillermo Garcia-Manero and Gautam Borthakur and Susan O'Brien and Farhad Ravandi and Jenny Shan and Jorge Cortes",
year = "2008",
month = "8",
day = "1",
doi = "10.1182/blood-2008-02-141580",
language = "English (US)",
volume = "112",
pages = "516--518",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

AU - Tam, Constantine S.

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

AU - Borthakur, Gautam

AU - O'Brien, Susan

AU - Ravandi, Farhad

AU - Shan, Jenny

AU - Cortes, Jorge

PY - 2008/8/1

Y1 - 2008/8/1

N2 - To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, patients achieving a major cytogenetic response (12MMCyR) had a significant survival advantage over patients in minor cytogenetic response or complete hematologic response, with a projected one-year survival of 97% and 84% respectively (P = .02). Projected 1-year progression to hematologic failure, accelerated phase, or blast phase was also significantly different (3% vs 17%, P =.003). Early cytogenetic response was strongly predictive of achievement of 12MMCyR, with less than 10% of patients showing no cytogenetic response at 3 to 6 months eventually attaining the target of 12MMCyR. These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies.

AB - To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, patients achieving a major cytogenetic response (12MMCyR) had a significant survival advantage over patients in minor cytogenetic response or complete hematologic response, with a projected one-year survival of 97% and 84% respectively (P = .02). Projected 1-year progression to hematologic failure, accelerated phase, or blast phase was also significantly different (3% vs 17%, P =.003). Early cytogenetic response was strongly predictive of achievement of 12MMCyR, with less than 10% of patients showing no cytogenetic response at 3 to 6 months eventually attaining the target of 12MMCyR. These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies.

UR - http://www.scopus.com/inward/record.url?scp=50949119729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949119729&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-02-141580

DO - 10.1182/blood-2008-02-141580

M3 - Article

C2 - 18492956

AN - SCOPUS:50949119729

VL - 112

SP - 516

EP - 518

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -